Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

Objective: Clinical phenomenology remains the primary means for classifying psychoses
despite considerable evidence that this method incompletely captures biologically …

Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …

Introduction Metastatic spread to the brain is common in patients with non–small cell lung
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials …